Burke Bioventures focuses on the application of new science and technology for better medicines. Thirty years ago, biologics fit this definition– and now they comprise 20% of biopharmaceutical drugs in development. 

\More recently, antibody-drug conjugates (ADC’s) have exploded with numerous partnerships and pipeline programs. While the concept of ADC’s is quite old – with the first companies formed over 30 years ago, and the original scientific vision articulated by Ehrlich over 100 years ago – within the past 10 years technical advances have turned this concept into an engine of clinical programs with some exciting new products emerging. At Burke Bioventures our mission is to identify and bring to fruition the next wave of biopharmaceutical innovation. If you are looking at a new product concept that relies on yet-to-be proven technology, we may be able to help. Our experience base crosses a wide range of therapeutic areas and classes of molecules.